Advance Therapy Revenue and Competitors
Estimated Revenue & Valuation
- Advance Therapy's estimated annual revenue is currently $8.6M per year.
- Advance Therapy's estimated revenue per employee is $216,000
Employee Data
- Advance Therapy has 40 Employees.
- Advance Therapy grew their employee count by -34% last year.
Advance Therapy's People
| Name | Title | Email/Phone |
|---|
Advance Therapy Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.3M | 156 | -3% | N/A | N/A |
#2 | $148.5M | 440 | N/A | N/A | N/A |
#3 | $124.2M | 368 | 46% | N/A | N/A |
#4 | $545.1M | 1442 | 17% | N/A | N/A |
#5 | $29.2M | 108 | 6% | N/A | N/A |
#6 | $12.9M | 53 | N/A | N/A | N/A |
#7 | $1125.1M | 2914 | 6% | $20.4M | N/A |
#8 | $15.3M | 63 | 15% | N/A | N/A |
#9 | $8.9M | 41 | 5% | N/A | N/A |
#10 | $4.3M | 23 | -15% | N/A | N/A |
What Is Advance Therapy?
Advance Therapy is a hospital & health care company based out of 1415 E Colorado St # 212, Glendale, California, United States.
keywords:N/A
N/A
Total Funding
40
Number of Employees
$8.6M
Revenue (est)
-34%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Advance Therapy News
2022-04-20 - Coeptis Combines with Bull Horn in SPAC Deal to Advance ...
CD38-GEAR-NK is a natural killer (NK) cell- based therapy candidate that supports combination treatment with anti-CD38 monoclonal antibodies (...
2022-04-19 - Novel CAR T Therapy for Solid Tumors: 'Exciting Advance'
Now, a new CAR T construct that targets the tumor-specific antigen claudin 6 (CLDN6) is showing promising preliminary activity against relapsed...
2022-04-13 - Cell therapy biotech raises $120M to advance therapy to treat common cornea
condition
Aurion Biotech has raised $120 million to advance its cell therapy for an eye disorder that affects millions of people.
Other Companies in Glendale
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $9.3M | 40 | 5% | N/A |
#2 | $10.4M | 40 | 8% | N/A |
#3 | $9.3M | 40 | 5% | N/A |
#4 | $10.6M | 40 | 5% | N/A |
#5 | $6.4M | 40 | 11% | N/A |